BioPharm America™ 2017: Morphic Therapeutics finds new approach for reaching targets

Praveen Tipirneni is the CEO of Morphic Therapeutic in Waltham, Mass. The company uses a computational platform to help it better determine the dynamic nature of drug targets, sort of like watching "movies" of drug targets instead of just relying on still photographs. Speaking at BioPharm America™ in Boston, Tipirneni described the approach, and the opportunity it sees with making drugs against integrins, a tantalizing class of targets that has proven elusive to drugmakers in the past.